Cargando…

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy

Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a progressive neurodegenerative disease that results in early-onset, severe, progressive, neurological disabilities, leading to death in late childhood or early adolescence. Management has relied on symptomatic care, and supportive and palliati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Specchio, Nicola, Pietrafusa, Nicola, Trivisano, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127909/ https://www.ncbi.nlm.nih.gov/pubmed/32280231 http://dx.doi.org/10.2147/TCRM.S241048

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
por: Kim, Aryun, et al.
Publicado: (2020)

POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings
por: Specchio, Nicola, et al.
Publicado: (2020)

Autism and Epilepsy in Patients With Tuberous Sclerosis Complex
por: Specchio, Nicola, et al.
Publicado: (2020)

Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses
por: Trivisano, Marina, et al.
Publicado: (2022)

Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series
por: Wibbeler, Eva, et al.
Publicado: (2020)

Is Cenobamate the Breakthrough We Have Been Wishing for?
por: Specchio, Nicola, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on pediatric patients with epilepsy – The caregiver perspective
por: Trivisano, Marina, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Quinidine in Pediatric Patients with KCNT1 Genetic Variants
por: Ferretti, Alessandro, et al.
Publicado: (2022)

Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep
por: Nelvagal, Hemanth R., et al.
Publicado: (2022)

Imbalance of Systemic Redox Biomarkers in Children with Epilepsy: Role of Ferroptosis
por: Petrillo, Sara, et al.
Publicado: (2021)

Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
por: Gissen, Paul, et al.
Publicado: (2021)

Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
por: Nickel, Miriam, et al.
Publicado: (2023)

Refractory Status Epilepticus in Genetic Epilepsy—Is Vagus Nerve Stimulation an Option?
por: Specchio, Nicola, et al.
Publicado: (2020)

Modeling PCDH19-CE: From 2D Stem Cell Model to 3D Brain Organoids
por: Borghi, Rossella, et al.
Publicado: (2022)

Epileptic Encephalopathy
por: Specchio, Nicola, et al.
Publicado: (2012)

Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes
por: Haney, Matthew J., et al.
Publicado: (2020)

Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)
por: Katz, Martin L, et al.
Publicado: (2014)

The Role of KRAS Mutations in Cortical Malformation and Epilepsy Surgery: A Novel Report of Nevus Sebaceous Syndrome and Review of the Literature
por: Pepi, Chiara, et al.
Publicado: (2021)

Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients
por: Mole, Sara E., et al.
Publicado: (2021)

Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment
por: Iwan, Katharina, et al.
Publicado: (2022)

Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
por: Soldati, Chiara, et al.
Publicado: (2021)

Timing of cognitive decline in CLN3 disease
por: Kuper, Willemijn F. E., et al.
Publicado: (2018)

Development of the “Hamburg Best Practice Guidelines for ICV−Enzyme Replacement therapy (ERT) in CLN2 Disease” Based on 6 Years Treatment Experience in 48 Patients
por: Schwering, Christoph, et al.
Publicado: (2021)

Characterizing PCDH19 in human induced pluripotent stem cells (iPSCs) and iPSC-derived developing neurons: emerging role of a protein involved in controlling polarity during neurogenesis
por: Compagnucci, Claudia, et al.
Publicado: (2015)

Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt
por: Fateen, Ekram, et al.
Publicado: (2021)

A comparative study of the degradation of yeast cyclins Cln1 and Cln2
por: Quilis, Inma, et al.
Publicado: (2016)

Data on characterizing the gene expression patterns of neuronal ceroid lipofuscinosis genes: CLN1, CLN2, CLN3, CLN5 and their association to interneuron and neurotransmission markers: Parvalbumin and Somatostatin
por: Minye, Helena M., et al.
Publicado: (2016)

Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme
por: Hahn, Andreas, et al.
Publicado: (2022)

Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis
por: Murray, Samantha J, et al.
Publicado: (2023)

Fatal Status Epilepticus in Dravet Syndrome
por: De Liso, Paola, et al.
Publicado: (2020)

Reply to Dravet, C. Different Outcomes of Acute Encephalopathy after Status Epilepticus in Patients with Dravet Syndrome. How to Avoid Them? Comment on “De Liso et al. Fatal Status Epilepticus in Dravet Syndrome. Brain Sci. 2020, 10, 889”
por: De Liso, Paola, et al.
Publicado: (2021)

Insights into cognitive and behavioral comorbidities of SLC6A1-related epilepsy: five new cases and literature review
por: Trivisano, Marina, et al.
Publicado: (2023)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis
por: Lopez-Fabuel, Irene, et al.
Publicado: (2022)

Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease
por: Mitchell, Nadia L., et al.
Publicado: (2023)

Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease
por: Murray, Samantha J., et al.
Publicado: (2023)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
por: Raucci, Umberto, et al.
Publicado: (2020)

Enzyme replacement therapy: efficacy and limitations
por: Concolino, Daniela, et al.
Publicado: (2018)

Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses
por: Russell, Katharina N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7fllt4648tbhtpo4b70s05i39q